Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Eliem Therapeutics, Inc. ELYM NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
37/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Eliem Therapeutics, Inc. (ELYM) — Analyst outlook / Analyst consensus target is. Based on 4 analyst ratings, the consensus is bullish — 2 Buy, 2 Hold.

ELYM Analyst Ratings

Buy
4
Ratings
2 Buy
2 Hold
Based on 4 analysts giving stock ratings to Eliem Therapeutics, Inc. in the past 3 months
Rating breakdown
Buy
2 50%
Hold
2 50%
50%
Buy
2 analysts
50%
Hold
2 analysts
0%
Sell
0 analysts

People Also View

PHVS
PHVS
Pharvaris N.V.
$28.68
+2.87%
 RZLT
RZLT
Rezolute, Inc.
$3.56
-1.36%
 STTK
STTK
Shattuck Labs, Inc.
$6.78
+0.15%
 IPSC
IPSC
Century Therapeutics, Inc.
$2.37
+4.41%
 MOLN
MOLN
Molecular Partners AG
$4.14
-1.66%
 ADAG
ADAG
Adagene Inc.
$3.81
-0.78%
 PRDS
PRDS
Pardes Biosciences, Inc.
$2.18
+0.93%
 PEPG
PEPG
PepGen Inc.
$1.69
+0.59%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message